For future understanding of biology, we have to get to grips with complexity. Most biological processes are based on complex networks involving many components. Because they have been generated by natural selection, redundancies and add-on functions abound, and some parts may only be relevant in specific circumstances. Occam's razor rarely applies. So how can sense be made of this complexity?
First, the components involved in the process of interest have to be identified. To do this, functional approaches are best, especially systematic gene deletions that eliminate all function, although knockdowns are also useful. However, both approaches lack the subtleties that can be revealed by point mutation. Monitoring gene activities through transcriptomics or proteomics are useful, but not all changes in expression during a process are of interest. Once the kit of parts has been identified, then their linkages can be determined through genetic or physical interactions. The consequent interactome generates a necessary description but unfortunately not always a better understanding.
For that, we need to know which parts of the network are at the heart of the process. One way is to simplify the network by eliminating functions whilst still maintaining the core process, through gene deletion, gene fusion, changing expression, or altering modification sites. It is a sort of reverse synthetic biology. Reducing the elements to the minimum will focus attention on those that are central to the process, and this should help gain better understanding.
A Threshold for Heart Attacks
Joseph L. Goldstein and Michael S. Brown University of Texas Southwestern Medical Center at Dallas 100 years ago, a Russian pathologist fed cholesterol to rabbits and produced atherosclerosis, thus indicting cholesterol as the perpetrator. Subsequent epidemiologic, genetic, and therapeutic data convicted cholesterol-carrying low density lipoprotein (LDL) as the culprit. LDL receptor mutations that increase LDL cause heart attacks in children. PCSK9 mutations that raise LDL receptors and lower LDL from birth reduce heart attacks in adults. Lowering LDL by diet or statins reduces heart attacks.
Genetics shows that lifelong reduction of LDL is more effective than lowering LDL later in life. Each person has a different threshold for LDL-induced heart attacks. If we knew this threshold, we would know whom to treat prophylactically, but how to identify the threshold? Risk factors-hypertension, smoking, diabetes, low HDL-lower the threshold and demand prophylaxis. But what about middle-aged people with ''average'' LDL and no risk factors? Common genetic variants are no help because their effects are small. We need a noninvasive method that detects the earliest stage of atherosclerosis. Biologists, epidemiologists, and drug inventors have done their job. Cardiologists and radiologists, please accept the challenge.
Thresholds are not unique to LDL. Susceptibility varies for all quantitative traits. To individualize thresholds, we need deeper knowledge of disease mechanisms-a challenge for all physician-scientists.
Telomeres' Ringside Seat

Carol Greider
Johns Hopkins University Telomeres punch above their weight. The study of chromosome ends has produced decades of remarkable discoveries. The telomere sequence of Tetrahymena, TTGGGG, was first decoded in 1978. Since then, a cascade of discoveries has linked telomeres to disease. Early studies in yeast and human cells laid the foundation for understanding the pivotal role of telomeres in cell survival. Following the discovery of telomerase, focus shifted to understanding how this remarkable enzyme synthesizes new telomere repeats. By examining the consequence of telomerase deletion, it became clear that short telomeres, not the absence of telomerase per se, causes cell death and senescence. Cells that divide must protect against telomere shortening, and so, cancer cells and adult stem cells alike critically depend on telomerase to cap telomeres. In humans, telomere syndrome is marked by short telomeres that are associated with bone marrow failure and pulmonary fibrosis as well as GI, liver, and other diseases. We are still discovering how this array of age-related degenerative diseases manifests in so many different tissues. Telomere biology has led the way in integrating fundamental discovery and clinical medicine, and both areas have been enriched. What are the hints for the future? There are known unknowns: new genes affecting telomeres, the mystery of telomere length equilibrium, and tissue-specific responses in telomere disease. But the excitement is, of course, in the unknown unknowns; the joy of discovery comes from completely unsuspected findings. It is thrilling to be ringside as the featherweight telomere moves up a weight class.
Immune Prowess against Cancer
David Baltimore
California Institute of Technology
In its natural state, our immune system fights cancer poorly. But there are two threads in modern biology that can interact to change that perspective. These are immunotherapy and gene medicine. Both are old hopes given new momentum by innovative research. For immunotherapy to work, immune killer cells need to recognize surface features of cancer cells, bind tightly, and activate their killing mechanism. In a minority of cancers, rare patients have such a response, some even enjoying a ''spontaneous cure''. But new research efforts are expanding the successes. One key strain of research is the discovery of ''Checkpoint Inhibitors'', proteins like anti-CTLA4 that take the brakes off immune cells. Another is the generation of engineered proteins that can recognize tumor cell surface molecules. Genes encoding these engineered binding proteins can be implanted into the genomes of a patient's own killer T cells (a form of gene therapy), directing the cells to kill the patient's tumor cells. For a few cancers, apparent cures are being recorded with these new methods. But more research is needed before we find targets on a majority of tumors and learn how to design targeting molecules for each tumor. The public has wondered why, after so many years of funding cancer research, we have made so little progress on the major killers. That perspective is changing and if we continue supporting innovative ideas, major progress can be expected in the next few decades in making our immune systems work more effectively for us.
Cell 157, March 27, 2014 ª2014 Elsevier Inc. 273
